Physician profile
Michael M Babich
NPI 1598764458
$157,069.46
in general payments reported to CMS, 2019-2025
23 companies · $67K in 2025
The $67K reported for 2025 was more than what 98% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $27K · 2020: $13K · 2021: $18K · 2022: $13K · 2023: $6,224 · 2024: $14K · 2025: $67K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $78K · Food and Beverage: $3,715 · Travel and Lodging: $3,622 · Consulting Fee: $1,080 · Education: $220.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $78,191.50 |
| Food and Beverage | $3,714.51 |
| Travel and Lodging | $3,622.28 |
| Consulting Fee | $1,080.00 |
| Education | $219.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $51,004.97 | 2024-2025 | Iqirvo, Bylvay |
| Gilead Sciences, INC. | $33,273.98 | 2019-2024 | Epclusa |
| Madrigal Pharmaceuticals | $28,844.75 | 2025 | Rezdiffra |
| Intercept Pharmaceuticals, INC. | $23,187.18 | 2019-2023 | Ocaliva |
| Abbvie INC. | $17,618.70 | 2019-2025 | Skyrizi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,250.00 | 2022 | |
| Janssen Biotech, INC. | $785.96 | 2019-2025 | Tremfya, Stelara |
| Mallinckrodt Hospital Products INC. | $290.24 | 2023-2025 | Terlivaz |
| Takeda Pharmaceuticals U.S.A., INC. | $210.58 | 2019-2024 | Entyvio |
| Stryker Corporation | $144.81 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $121.08 | 2023 | |
| Phathom Pharmaceuticals, INC. | $62.70 | 2025 | Voquezna |
| Cook Medical LLC | $44.19 | 2022-2025 | Hemospray |
| Shionogi INC | $38.11 | 2019 | |
| Amgen INC. | $29.80 | 2023 | Amjevita, Avsola |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $28.13 | 2024 | |
| Genzyme Corporation | $25.68 | 2025 | |
| Ironwood Pharmaceuticals, INC | $24.83 | 2023 | Linzess |
| Medtronic, INC. | $21.76 | 2023 | Eleview |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.07 | 2023 | Cyltezo |
| Braintree Laboratories, INC. | $16.12 | 2022 | |
| Ardelyx, INC. | $15.65 | 2025 | Ibsrela |
| Allergan, INC. | $11.17 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Babich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.